Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Regeneron and Sanofi are seeking to expand the use of Dupixent to include more conditions, including chronic obstructive pulmonary disease (COPD), chronic spontaneous Urticaria (CSU) and bullous ...

For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study.

Sanofi and Regeneron’s blockbuster biologic Dupixent ... asthma and chronic obstructive pulmonary disease (COPD). Sanofi reported in its Q4 2024 results that Dupixent surpassed its €13bn ...

Second, Regeneron's other growth driver, eczema treatment Dupixent -- the rights of which it shares with Sanofi-- is doing great. Fresh off a label expansion in treating COPD last year ...

Though the most important is a new indication in COPD the drug earned last year, there are others. Regeneron and Sanofi are also seeking a label expansion for Dupixent in treating a rare skin ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.